Literature DB >> 6933866

Postirradiation osteosarcoma in childhood. A clinicopathologic study of three cases and review of the literature.

J Varela-Duran, L P Dehner.   

Abstract

Three cases of postirradiation osteosarcoma which presented in childhood are reported and the pertinent literature reviewed. The children had been treated in each instance before the age of 3 years for an astrocytoma, retinoblastoma, and neuroblastoma, respectively. An average latent interval of 9.5 years lapsed before the osteosarcomas were diagnosed. Two of the tumors occurred in unusual sites, the cervical vertebrae and maxilla but were within the fields of prior irradiation. The tumors were predominantly sclerotic and were high-grade osteosarcomas. Only one patient has remained free of disease after treatment. One tumor-related death has occurred and the third patient has had two wedge resections of pulmonary metatases.

Entities:  

Mesh:

Year:  1980        PMID: 6933866

Source DB:  PubMed          Journal:  Am J Pediatr Hematol Oncol        ISSN: 0192-8562


  4 in total

1.  Radiation induced osteogenic sarcoma of the maxilla.

Authors:  Om Prakash; Bipin T Varghese; Anita Mathews; Nileema Nayak; Krishnankutty Ramchandran; Manoj Pandey
Journal:  World J Surg Oncol       Date:  2005-07-21       Impact factor: 2.754

2.  Case report 714. Postirradiation osteosarcoma after radiation of metastatic skeletal lesion.

Authors:  B C Toorkey; K K Unni; D C Dahlin
Journal:  Skeletal Radiol       Date:  1992       Impact factor: 2.199

Review 3.  Primary bony tumors of the pediatric spine.

Authors:  G N Graham; H Browne
Journal:  Yale J Biol Med       Date:  2001 Jan-Feb

4.  Secondary radiation-induced bone tumours demonstrate a high degree of genomic instability predictive of a poor prognosis.

Authors:  Christine Rümenapp; Jan Smida; Iria Gonzalez-Vasconcellos; Daniel Baumhoer; Bernard Malfoy; Nabila-Sandra Hadj-Hamou; Bahar Sanli-Bonazzi; Michaela Nathrath; Michael J Atkinson; Michael Rosemann
Journal:  Curr Genomics       Date:  2012-09       Impact factor: 2.236

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.